International Journal of Hematology and Oncology 2019, Vol 29, Num 4 (Special Issue) Page(s): 018-023
Advanced Phase Chronic Myeloid Leukemia Treatment and Transplantation

Zafer GULBAS

Anadolu Medical Center Hospital, Bone Marrow Transplantation Center, Kocaeli, TURKEY

Keywords: Chronic myeloid leukemia, Allogeneic hematopoietic stem cell transplantation, Imatinib, Tyrosine kinase inhibitors
Imatinib and second generation tyrosine kinase inhibitors has dramatically improved outcomes in patients with chronic myeloid leukemia but allogeneic hematopoietic stem cell transplantation remains an important treatment option in patients who failed imatinib and or second generation second generation tyrosine kinase inhibitors or progressed accelerated and blastic phase. This article provides recommendations regarding the selection of allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia based on the evaluation of published articles and expert recommendations.